31 results about "Treatment-resistant depression" patented technology

The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses.

Disclosed herein are novel assays, systems and kits for selecting a treatment regimen for a subject with depression by identifying at least one nucleic acid polymorphism, e.g., but not limited to, at the MTHFR, MTR, or MTRR locus, and/or determining expression levels of peripheral biomarkers (e.g., SAM, SAH, and 4-HNE) in a test sample from a human subject. These biomarkers can be used to determine the effectiveness of treating a depressed subject with a folate-containing compound (alone or as an adjunct to an antidepressant). Additionally, these biomarkers can be used to select an appropriate treatment regimen for subjects with treatment-resistant depression (e.g., resistant to at least one selective serotonin reuptake inhibitor). Methods and compositions for treating a subject with depression and/or determining or improving the effectiveness of an antidepressant drug taken by a subject are also provided herein.

The invention discloses a primer group, a kit and a detection method for detecting genes related to individualized medication for depression. The primer group is selected from nucleotide sequences inSEQ ID NO.1-SEQ ID NO.154. The detection kit covers eight major categories of clinical first-line and second-line antidepressant efficacy-related genes, and relates to drug metabolism, target spots and transporter gene loci, and detection is conducted comprehensively and accurately. Accordingly, aiming at part of patients suffering from treatment-refractory depression, gene detection related to the therapeutic effect of antidepressant synergistic drugs is added, and powerful support is provided for selection of therapeutic schedules of the treatment-refractory depression.

The present invention is directed to method for the treatment of depression, for example, treatment resistant depression; wherein the treatment regimen is adjusted depending on the patient's genotype at SNP rs4306882.

Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome.

The present invention relates to methods for the treatment of treatment-resistant depression (TRD), comprising the administration of compounds of formula (I), which are blocked in C₃ position and cannot metabolize in vivo into pregnenolone derivatives and which do not have significant affinity for steroid hormonal receptors and for all tested classical main receptors and receptors of neurotransmitters of the central nervous system.

The present invention relates to 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds of the formula:

A method treats patient with treatment resistant depression, adjunct to standard antidepressant treatment or as monotherapy. These patients will be identified by non-response to at least one pharmacological antidepressant treatment with a sufficient dose and over a sufficient period of time. Further, one embodiment of the method includes a procedure to identify patients who would benefit from a combination of standard antidepressants with the described compounds from the start of the treatment in order to maximize the likelihood of response. Another embodiment of the method combines the described compounds with forms of Magnesium salts in order to overcome longer term tolerability issues with the compounds. An important downstream mechanism of the described interventions is the property to reduce the production and or increase the absorption of cerebrospinal fluid to treat a variety of symptoms, including cognitive dysfunction, memory loss, apathy, sleep disturbances, pain disorders, and somatoform pain and headache.

Methods and compositions are disclosed for rapidly reducing the risk of suicide in patients suffering from acute suieidality and rapidly relieving mood symptoms in major depression and treatment-resistant depression using a novel therapeutic regimen comprising a single or intermittent administration of a high dose of gaboxadol, or a pharmaceutically acceptable salt thereof, to the subject in need thereof.

The present invention generally relates to the use of 25% nitrous oxide for treating patients with a treatment-resistive depressive disorder and compositions useful for the same.

The invention provides application of glycyrrhizic acid and a pharmaceutically acceptable salt thereof to preparation of antidepressant drugs, and specifically, application of the glycyrrhizic acid and the pharmaceutically acceptable salt thereof to preparation of the antidepressant drugs as a sole active component, application of the glycyrrhizic acid and the pharmaceutically acceptable salt thereof as an antidepressant drug synergist or application of the glycyrrhizic acid and the pharmaceutically acceptable salt thereof to treatment of treatment-refractory depression with combined application of the antidepressant drugs. According to the invention, clinical tests show that the glycyrrhizic acid and/or the pharmaceutically acceptable salt of the glycyrrhizic acid can achieve obvious synergistic effect on the antidepressant drugs and can rapidly, safely and effectively improve symptoms of depression in clinical application; therefore, the glycyrrhizic acid and/or the pharmaceuticallyacceptable salt of the glycyrrhizic acid can be used as the sole active component for preparing the antidepressant drugs, can be used for preparing the antidepressant drug synergist or can be appliedto treatment of treatment-refractory depression with combined application of the antidepressant drugs, can be applied to treatment of different depression, can improve the antidepressant effects of the drugs, is cheap, easily available, safe and non-toxic, and has good clinical application prospects.